A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Alector, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 3,520 shares of ALEC stock, worth $13,868. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,520
Previous 2,878 22.31%
Holding current value
$13,868
Previous $13,000 23.08%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$4.34 - $6.58 $2,786 - $4,224
642 Added 22.31%
3,520 $16,000
Q2 2024

Jul 30, 2024

SELL
$4.19 - $6.23 $208,515 - $310,035
-49,765 Reduced 94.53%
2,878 $13,000
Q1 2024

May 01, 2024

SELL
$5.69 - $8.08 $48,911 - $69,455
-8,596 Reduced 14.04%
52,643 $316,000
Q4 2023

Jan 24, 2024

BUY
$3.77 - $8.39 $7,992 - $17,786
2,120 Added 3.59%
61,239 $488,000
Q3 2023

Oct 26, 2023

BUY
$5.2 - $8.77 $21,392 - $36,079
4,114 Added 7.48%
59,119 $383,000
Q2 2023

Aug 10, 2023

BUY
$5.86 - $7.93 $12,200 - $16,510
2,082 Added 3.93%
55,005 $330,000
Q1 2023

May 04, 2023

BUY
$5.85 - $9.84 $83,187 - $139,924
14,220 Added 36.74%
52,923 $327,000
Q4 2022

Feb 09, 2023

BUY
$6.88 - $9.55 $220 - $305
32 Added 0.08%
38,703 $357,000
Q3 2022

Nov 10, 2022

BUY
$8.19 - $13.2 $65,405 - $105,415
7,986 Added 26.03%
38,671 $365,000
Q2 2022

Jul 26, 2022

BUY
$7.65 - $14.24 $152,342 - $283,575
19,914 Added 184.89%
30,685 $311,000
Q1 2022

May 10, 2022

SELL
$13.02 - $20.78 $14,165 - $22,608
-1,088 Reduced 9.17%
10,771 $153,000
Q4 2021

Feb 08, 2022

BUY
$19.35 - $25.54 $19,175 - $25,310
991 Added 9.12%
11,859 $245,000
Q3 2021

Nov 15, 2021

BUY
$21.65 - $39.49 $26,629 - $48,572
1,230 Added 12.76%
10,868 $248,000
Q2 2021

Aug 11, 2021

BUY
$15.5 - $22.48 $149,389 - $216,662
9,638 New
9,638 $201,000

Others Institutions Holding ALEC

About Alector, Inc.


  • Ticker ALEC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,563,904
  • Market Cap $325M
  • Description
  • Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...
More about ALEC
Track This Portfolio

Track Mirae Asset Global Investments Co., Ltd. Portfolio

Follow Mirae Asset Global Investments Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.